A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: SAR445399
DRUG: Placebo

Sponsor

Sanofi